Articles tagged with Alzheimer Disease
ResearchersAgainstAlzheimer's report reveals 57 new Alzheimer's drugs in Phase II testing, with nearly twice as many mechanisms of action being tested as in Phase III clinical trials. The analysis calls for changes to clinical trial infrastructure and endpoints to ensure rapid recruitment and effective testing.
Researchers found that mice can maintain learning and memory when virtually all ApoE is removed from the brain, as long as it remains present in the liver to filter cholesterol. This study supports the belief that reducing ApoE in the brain could be a viable therapeutic option for treating Alzheimer's.
Research reveals that 56% of people aged 90 and above with Alzheimer's disease rely on antipsychotics and antidepressants, highlighting the need for regular assessment of drug use in older adults. In contrast, those without Alzheimer's disease used these medications less frequently.
A new imaging technique using tau PET has been confirmed to accurately depict changes in the brain associated with Alzheimer's disease. The method reveals tau protein accumulation, which is linked to cell death and can be targeted by new drugs.
A study by Rush researchers found that TDP-43, a previously recognized pathologic protein, is more likely to result in diagnosed Alzheimer's dementia when combined with plaques and tangles. Mixed pathologies increase the risk of developing Alzheimer's dementia above and beyond just having these brain abnormalities.
Researchers found that lysozyme increases in the brains of Alzheimer's patients and has favorable effects on fly models of the disease. The findings indicate that lysozyme may represent a clinical marker for Alzheimer's and a potential therapeutic strategy to slow disease progression.
Researchers at the University of Bristol have developed a set of guidelines for assessing vascular cognitive impairment, which can help determine the likelihood that cognitive decline was caused by vascular disease. The guidelines are based on pathological criteria and can be used to streamline research into dementia.
Aducanumab, a human monoclonal antibody, selectively binds to brain amyloid plaques, allowing microglial cells to remove them. After one-year treatment, almost complete clearance of brain amyloid plaques was observed in patients.
The Alzheimer's Association has launched a new initiative to explore potential sex differences in Alzheimer's disease. Emerging evidence suggests that biological or genetic differences may contribute to the higher frequency of Alzheimer's in women, and researchers will investigate hormone, genetics, and lifestyle factors. The goal is t...
Researchers have identified a critical protein associated with Alzheimer's disease symptoms, suggesting a new target for therapy. The study shows that increasing p62 levels may reverse the effects of damaging plaques in the brain through autophagy.
A study found that caffeine and its analogues restore memory deficits by addressing abnormal stress response mechanisms in the brain. Researchers normalized aging-like profiles in rats, reversing memory impairments linked to increased stress hormones.
Scientists have identified the β2 subunit of nicotinic receptors as a direct target of soluble amyloid beta peptide, which builds up in the brain and leads to Alzheimer's disease. Blocking this receptor prevents memory loss and cognitive decline in mouse models.
Scientists at the Medical College of Georgia have found that vesicles that trap amyloid contribute to Alzheimer's disease. Reducing exosome production may help reduce amyloid accumulation and slow disease progression. However, female mice did not reap similar benefits, suggesting potential gender-specific differences in the disease.
New research boosts levels of neuregulin-1 to alleviate hallmark features of Alzheimer's disease in a mouse model, promoting metabolism of brain plaques. The study suggests that neuregulin-1 may improve performance on spatial memory tests and lower cellular markers of disease.
UCSB neuroscientist Kenneth Kosik advocates for fundamental cell biology research into neurodegeneration, which may accelerate understanding of Alzheimer's and Parkinson's diseases. He argues that basic science provides a foundation for treatments beyond single diseases and early detection.
Researchers developed a multivariate approach to improve cognitive testing for Alzheimer's disease, identifying five distinct patient groups. The model suggests that multivitamins may slow progression only in certain groups, particularly those with mild impairment in recalling.
The Generation Study will enroll over 1,300 cognitively healthy older adults at high risk of developing Alzheimer's due to inherited APOE gene mutations. Researchers will test two investigational treatments: an active immunotherapy and an oral medication to stop amyloid accumulation.
Researchers at Salk Institute identify a connection between ApoE4 and protein build-up associated with Alzheimer's, providing a possible biochemical explanation for extra ApoE4 causing the disease. They also found that ApoE4 keeps the enzyme HtrA1 from breaking down tau protein, responsible for tau tangles associated with Alzheimer's.
A UCLA study found that a healthy diet, regular physical activity, and normal body mass index can lower plaque and tangle levels in the brain. Lifestyle factors such as a Mediterranean diet were shown to directly influence abnormal proteins in people with subtle memory loss.
The Michigan Alzheimer's Disease Core Center will support researchers and clinicians from three major universities in developing new treatments and understanding the causes of dementia. The center aims to provide training opportunities across many areas of research and facilitate collaboration among experts.
Researchers have successfully treated an experimental model of Alzheimer's disease with mefenamic acid, a commonly used anti-inflammatory drug. The study found complete reversal of memory loss and brain inflammation in mice, paving the way for human trials.
Researchers discovered a link between slow walking speeds, weak grip strength, and increased risk of Alzheimer's disease and stroke in individuals over 65. These simple tests may help identify high-risk patients, providing hope for early detection and prevention.
A gene signature in healthy brains predicts the spread of Alzheimer's disease and identifies vulnerable brain regions. The discovery may lead to preventative treatments for at-risk individuals.
Researchers explore Fasudil as a therapeutic option for Alzheimer's disease, finding it reduces Aβ deposition, Tau phosphorylation, and inflammation. The treatment also improves learning and memory deficits in APP/PS1 transgenic mice.
A European and US research team has successfully determined the structure of the most disease-relevant beta-amyloid peptide 1–42 fibrils at atomic resolution. The findings simplify the targeted search for drugs to treat Alzheimer's dementia, offering hope for a potential cure in the next decade.
A study found an association between lower body mass index and greater deposits of Alzheimer's-associated protein beta-amyloid in the brains of older individuals, particularly those carrying the APOE4 gene variant. This may indicate that being underweight late in life increases the risk of developing Alzheimer's disease.
The University of Pennsylvania's Alzheimer's Disease Core Center has been awarded $8.8 million over five years from the National Institute on Aging to investigate Alzheimer's disease and related dementias. The center will focus on recruiting, studying subjects with early-stage AD, and expanding its bioinformatics infrastructure.
The Alzheimer's Association has launched a $7 million challenge to accelerate Alzheimer's disease therapy, focusing on brain inflammation and the immune system. Four cutting-edge clinical trials will receive $1 million each to advance research, with the goal of unlocking new treatments for this devastating disease.
A new review explores potential antioxidant approaches for Alzheimer's, Parkinson's, and other neurodegenerative diseases. Certain compounds targeting oxidative stress pathways, such as Nrf2, are being investigated.
Researchers at NYU Langone Health have identified a new target for preventing Alzheimer's disease, targeting the mechanism behind neural and vascular death. The study suggests that Carbonic Anhydrase Inhibitors may be effective in delaying symptom onset and improving quality of life for patients.
Researchers at Georgetown University Medical Center have found that cancer drug pazopanib decreases levels of phosphorylated Tau, a toxic brain protein linked to dementia in Alzheimer's and Parkinson's diseases. The study suggests that tau pathology may be the main culprit behind dementia in Alzheimer's disease.
Researchers at Georgetown University Medical Center found that resveratrol reduces neuronal inflammation and slows cognitive decline in Alzheimer's patients. The study shows that resveratrol activates proteins to decrease matrix metalloproteinase-9 levels, maintaining the blood-brain barrier.
Researchers have unveiled a new diagnostic tool that can identify Alzheimer's disease long before the onset of symptoms using a non-invasive eye scan. The tool, developed by Professor Melanie Campbell, uses polarized light to highlight amyloid protein deposits in the retina.
Researchers found that low UPSIT scores predicted dementia and cognitive decline in older adults, while entorhinal cortical thickness was associated with UPSIT score in those who transitioned to dementia. Odor identification testing may be useful in detecting early-stage Alzheimer's disease.
The Health-eBrain Study launches Phase II to investigate the impact of Alzheimer's caregiving on brain and behavioral health. An international cohort of caregivers will use a mobile app to assess their cognitive function over 12 weeks, tracking stress levels, sleep, mood, and self-evaluation of memory.
A new study suggests that a long version of waxy ceramide, often found in skin creams and shampoos, plays a critical role in supporting brain cells called astrocytes. The researchers aim to understand how this lipid regulates cilia on brain cells and prevent neurodegeneration associated with Alzheimer's disease.
Researchers have identified the first case of Alzheimer's disease in an HIV-positive individual, challenging existing knowledge about dementia in people with HIV. The discovery highlights the need for timely diagnosis and treatment of Alzheimer's disease in this population.
A new study published in JAMA Neurology found that tau imaging using [18F]-AV-1451 PET tracing distinguished participants with Alzheimer's from those who were cognitively normal. Elevated binding was also associated with volume loss in parts of the brain.
Scientists at University of Sussex have created a new protein resembling Abeta, which doesn't form clumps and is not toxic. This new tool will help researchers understand the causes of Alzheimer's disease and potentially find a cure.
A study by Dr. Kalipada Pahan found that cinnamon improves learning in poor mice by increasing sodium benzoate, a chemical produced as cinnamon breaks down in the body. The effect appears to be due mainly to sodium benzoate's ability to stimulate hippocampal plasticity and enhance the structural integrity of brain cells.
Researchers found that long-term antibiotic treatment decreased levels of amyloid plaques and activated inflammatory microglial cells in mice brains, while altering the gut microbiome. The study suggests a link between the gut microbiome's composition and immune system activity impacting Alzheimer's disease progression.
Researchers have identified a link between the TREM2 gene and immune cell dysfunction in Alzheimer's disease. Studies found that variants of this gene can impair the brain's ability to clear amyloid-beta aggregates, a hallmark of the disease.
Researchers at University Hospitals Case Medical Center are conducting a clinical trial using Philips fMRI Scanner to detect brain activation in patients with early and middle stages of Alzheimer's. The study aims to develop faster and more precise real-time methods for fMRI experimentation, which may help improve diagnosis accuracy.
A toxic Alzheimer's protein can spread through the brain via the extracellular space, jumping from neuron to neuron. The spread of tau may explain why only one area of the brain is affected in early stages but multiple areas are affected later.
Researchers at University of Cambridge identify mechanism behind rapid protein build-up in Alzheimer's disease, finding healthy proteins on fibrils drive self-replication. This discovery may lead to new ways to control plaque formation and slow disease progression.
Scientists use iDISCO clearing method to visualize brain tissue from deceased patients with Alzheimer's disease, exposing nonrandom structures of beta amyloid plaques. This breakthrough finding may lead to new targeted drugs and a better understanding of the relationship between plaque presence and disease severity.
Researchers found a significant association between delirium and long-term cognitive decline in older surgical patients. The study, published in Alzheimer's & Dementia, suggests that delirium may serve as a marker for seniors with poor cognitive reserve.
A study found that children with the epsilon-4 gene variant had differences in brain development compared to those with epsilon-2 and epsilon-3 variants, including smaller hippocampus size and lower test scores on memory and thinking skills. The findings suggest early indications of risk for dementia and potential prevention strategies.
A new study has revealed multiple leads for pursuing potential treatments for Alzheimer's disease by targeting a structural flaw in brain cells. The researchers found that the tau protein aggregates in the brains of patients disrupt the lamin nucleoskeleton, leading to DNA relaxation and gene activation.
A Big Data study has identified decreased blood flow in the brain as the earliest physiological sign of Alzheimer's disease. The researchers analyzed over 7,700 brain images and found that changes in cognition begin earlier than previously believed.
A recent study found that estrogen therapy via skin patch reduced beta-amyloid deposits in the brains of newly postmenopausal women, potentially decreasing Alzheimer's disease risk. Women with a greater genetic risk for Alzheimer's, such as those with the APOE e4 genotype, particularly benefited from this therapy.
Researchers have created a new technology to detect Alzheimer's progression in the retina of mice before symptoms appear, paving the way for early diagnosis and treatment. This breakthrough could help develop effective treatments well before patients show actual neurological signs.
A new molecule, rhenium dipyridophenazine complex, has been discovered that glows brighter when bound to amyloid protein fibrils implicated in Alzheimer's disease. This enables real-time monitoring of plaque aggregation, a key step in the development of potential treatments.
Research found no association between traumatic brain injury and dementia or Alzheimer disease, but increased risk of Parkinson's disease, progression of parkinsonism, and microinfarcts were observed. The study analyzed data from over 7,000 participants with a history of traumatic brain injury.
Researchers linked traumatic brain injury with later development of Parkinson's disease, but not Alzheimer's disease or incident dementia. The study, involving over 7,000 participants, found an association between TBI and Parkinson's disease, contradicting common assumptions about the relationship between TBI and Alzheimer's.
Researchers have developed an AI-powered MRI technique that can detect early forms of dementia, including mild cognitive impairment and Alzheimer's disease. The technique uses machine learning to analyze perfusion maps created by arterial spin labeling (ASL) imaging, with high accuracy in distinguishing between patients.
Researchers found that a genetic risk score was associated with worse memory and smaller hippocampus volume in healthy younger participants. A higher polygenic risk score was linked to greater longitudinal memory and executive function decline and clinical progression of the disease.
Researchers discovered that tiny micro-vesicle structures in blood carry tell-tale proteins associated with Alzheimer's disease, enabling the prediction of mild cognitive impairment (MCI) progression. The findings represent a quicker and less invasive way to identify impending cognitive decline.
Researchers have found a brief, simple test to effectively screen for cognitive impairment in Alzheimer's disease (AD), including mild cognitive impairment (MCI) and AD dementia. The King-Devick test can accurately distinguish between cognitively healthy individuals and those with cognitive impairment over 90% of the time.
Researchers developed a mouse model that mimics human Alzheimer's disease, showing that beta-amyloid accumulation is insufficient to trigger tau clumping alone. The study suggests combination therapy targeting both processes may be effective in preventing the disease.